These findings suggest that the 1-year treatment regimen with benralizumab for patients with severe asthma reduces peripheral blood eosinophils, increases Th2 cells and serum eotaxin-1 levels, and transiently increases serum IL-5 levels. Here, IL5 is linked to asthma.